CNS 2016_Brochure

CNS 2016
conferenceseries.com
Brochure
http://cns.conferenceseries.com/
Conference Secretariat
2360 Corporate Circle, Suite 400, Henderson, NV 89074-7722, USA
Phone: + 1-888-843-8169, Fax: +1-650-618-1417, Toll Free: +1-800-216-649
Email: cns@neuroconferences.com
Dubai, UAE December 05-07, 2016
2nd
International Conference on
CentralNervousSystemDisordersandTherapeutics

CNS 2016
OMICS International welcomes you to attend the 2nd
Central Nervous System Disorders and Therapeutics during December 05-07, 2016 at
Dubai, UAE.
We cordially invite all the participants who are interested in sharing their knowledge
and research in the arena of Neurology.
CNS 2016 anticipates more than 300 participants around the globe with thought
provoking Keynote lectures, Oral and Poster presentations. The attending delegates
include Editorial Board Members of related OMICS International Journals.
This is an excellent opportunity for the delegates from Universities and Institutes to
interact with the world class Scientists.
The intending participants can confirm their participation by registering for the
conference along with your colleagues. Avail the delegate early bird offer.
The main theme of the conference is “Accelerate the Diagnosis, Prevention &
Management of CNS disorders”.
Regards,
CNS 2016 Organizing Committee
Invitation

CNS 2016
Adam Kaplin
Montel Williams MS Foundation
USA
Aguinaldo Pereira Catanoce
University Hospital Technical Puc
Campinas, Brazil
Ali Savas
Ankara University, Turkey
Arif Khan
American Centre for Psychiatry and
Neurology, UAE
Brian J Cummings
University of California, USA
David Bonovich
San Ramon Regional Medical
Center, Pacific Rim Neurovascular
Associates, Sutter Health, USA
Dionisio Figueiredo Lopes
Hospital Urgencia Otavio Lage
Brazil
Fabio Bianco
Neuro-Zone, Sanipedia Ltd, Italy
Hiroyuki Nakase
Nara Medical University, Japan
Huma Sheikh
Mt Sinai Beth Israel, USA
Joanna B Strosznajder
Mt Sinai Beth Israel, Poland
Kate McLellan
KM Clinical Research Group, USA
Lilianne R Mujica Parodi
Stony Brook University School of
Medicine, USA
Maria A Nagel
University of Colorado School of
Medicine, USA
Martin J Stransky
Yale University, USA
Mohamed Farah
Johns Hopkins University, USA
Roberto Villa Federico
University of Pavia, Italy
Rwoof A Reshi
University of Minnesota, USA
Song Guo Zheng
Penn State University Hershey Col-
lege of Medicine, USA
TANG Wai Kwong
The Chinese University of Hong-
kong, China
Tissa Wijeratne
Western Health, Australia
Wissam Barada
American Center for Psychiatry and
Neurology, UAE
Organizing Committee Members

CNS 2016
Tentative Speakers
Nataiila Melynk, National Medical University, Ukraine
Suad Alanzi, Curtin University, Kuwait
Dionisio Figueiredo Lopes, Hospital de Urgencia Otavio Lage, Brazil
Fatima Laraba-Djebari, USTHB, Algeria
Elena Solntseva, Lomonosov Moscow State University, Russian Federation
Arash Khameneh Bgheri, Mashhad University of Science, Iran
Deeba Noreen Baig, Forman Christian College University, Pakistan
Nahla Nagy, Ain Shams University Egypt
Sina Salehi, Shiraz University of Medical Sciences, Iran
Ebthial Eltyeb, Omdurman Islamic Universit, Sudhan
Rwoof Reshi, University of Minnesota, USA
Yasamin Ghazvini Kor, Mafraq Hospital, UAE
Swarupa Mitra, Rajiv Gandhi cancer Institute & Research Centre, India
Ksenija Fumić, University Hospital Center Zagreb, Croatia
Barbora Slavikova, Institute of Organic Chemistry and Biochemistry,
Academy of Sciences, Czech Republic
Hana Chodounska, Institute of Organic Chemistry and Biochemistry,
Academy of Sciences, Czech Republic
Eva Kudova, Institute of Organic Chemistry and Biochemistry, Acad-
emy of Sciences, Czech Republic
Hiroyuki Nakase, Nara Medical University, Japan
Chinnu Selim, Central Food Technological Research Institute, India
Yafa Alshamlan, Saudi Arabia
Olga Kopach, UCL Institute of Neurology, UK
Seema Lalani, Baylor College of Medicine, USA
Joanna Strosznajder, Mossakowski Medical Research Centre, Polish
Academy of Sciences, Poland
Song Guo Zheng, Penn State University Milton. S. Hershey Medical
Center, USA
Abdolreza Esnaashari, Akershus University Hospital, Norway
Edward Kachur, McMaster University Faculty of Health Sciences, Canada
Nicola Salvatore Orefice, Federico II University, France
Lu Lu, Tianjin Medical University , China
Yash Patel, McMaster University, Canada
Angel Horcajadas, Vithas Hospital Health, Spian
Eileen Thomas, University of Cape Town, South Africa
Arpad Szallasi, Drexel University College of Medicine, USA
Liam Chen, Johns Hopkins University, USA
Brian J Cummings, University of California, USA
Ahmed Al Jishi, McMaster University Health Center, Canada
Philippe Bergonzo, French Atomic Energy Commission, France
Ma Xun Tai, Southwest Medical University, China
Svetlana Tomic, University of Josip Juraj Strossmayer in Osijek, Croatia
Jose Luis Acha Sanchez, National University of San Marcos, Peru
Hassan Barnawi, Taibah Medical College, Saudi Arabia
Nadia Hafizi Rastabi, Tehran University of Medical Sciences, Iran
Aguinaldo P. Catanoce, Pontificia Catholica University of Campinas,
Brazil
Emmanuel Iwuozo, Federal Medical Centre, Nigeria
Shuo Wang, California Institute of Technology, USA
Sophia Bakhtadze, Tbilisi State Medical University, Georgia
Wudassie Melak, Jimma University, Ethiopia
Cao Fei, Huazhong University of Science and Technology, China
Ajay Bajaj, Wockhardt Hospitals LTd., India
Ali Savas, Ankara University, Turkey
Diane Robert Stoler, Harvard University, USA

CNS 2016
11th
Global Dermatologists AnnualMeeting
Nov 14-16, 2016 Dubai, UAE
15th
Global Diabetes Summit and Medicare Expo
9th
Global Obesity Meeting
5th
Global Respiratory and Pulmonologist
Annual Meeting
International Conference and Exhibition on
Medical Writing and Healthcare Communications
8th
Global Summit and Expo on
Healthcare
10th
Clinical & Experimental Ophthalmology
13th Global Oncologists Summit and Cancer Therapy
Intensive and Cricalcare Nursing
Radiography
3rd International Conference on
Gynecology & Obstetrics
International Pharmaceutical Methods Development and
Validation Conference
5th
Petrolium Geology and Petrolium Industry
8th
Clinical Nutrition
2nd
Global Summit and Expo on
Biomass
Dec 5-6, 2016 Dubai, UAE
2nd
CNS Treatment
4th
Fitness, Health & Wellness
International Food Safety, Quality and Policy Conference
Burj al-Arab
Burj Khalifa
Sharjah Museum of Islamic Civilisation
Sheikh Zayed Grand Mosque
Dubai Aquarium
Cross your Country Borders! Plan your Trip to UAE
Great Meeting Destination for International Delegates

CNS 2016
Greetings from the Mayor
Greetings!
As Mayor of Phoenix, I take great pride in welcoming all the attendees of the 2nd International Conference on
Parkinson’s Disease and Movement Disorders. Parkinson’s is one of the most common neurological disorders, impacting
15-20 people out of every 100,000.
The number may seem small, but the disease has an immense impact on these families, with annual cost above
$10,000 per patient. There are, however, many people working to fight the disease. To help find a cure, the National
Institute of Neurological Disorders and Stroke awarded $90 millionto Parkinson’s disorder research, supported by the National Institute
of Health.With approximately 500 neurologists, psychiatrists and neurosurgeons in Phoenix alonededicated to researching and fighting
Parkinson’s disease, Phoenix is part of the solution.On behalf of the residents of Phoenix, I welcome you to our city, and wish you a
successful conference.
Greg Stanton
City Of Phoenix
Office of the Mayor
Phoenix
Greetings from the Nobel Laureate
Dear Colleagues,
As a Member of the Organizing Committee, I wish to extend a warm welcome to all the participants.
Even though a new era in the history of Parkinson’s disease started with the discovery of the role of
dopamine, the introduction of levodopa and an arsenal of dopamine-supporting drugs more than half a
century ago, leading to a dramatic improvement in the patients’ quality of life and longevity, the situation
for a Parkinson patient is still far from satisfactory, and the need for further research in this disorder is
urgent. Especially, after a varying number of years the presently available drugs start to loose much of their efficiency,
with disturbing side effects more and more taking over the scene. I wish to welcome all researchers from the fields
of basic neuroscience, neurology, and neurosurgery to contribute with your valuable expertise, and to stimulate
interdisciplinary endeavour.
Arvid Carlsson
Nobel Prize in Physiology/
Medicine for 2000
Greetings from the Governor
Greetings!
As Governor of the State of Nevada, it is with great pleasure that I welcome you to participate at OMICS International
Inc. Conferences. The OMICS International through its Open Access initiative is committed to make genuine and reliable
contributions to the scientific community. OMICS International Conferences make the perfect platform for global
networking as it brings together renowned speakers and scientists across the globe. I commend you for having exciting
and memorable events filled with enlightening interactive sessions. Thank you for bringing this dynamic exposition to
our great state.
As Governor of the great State of Nevada, I would like to express my appreciation to the OMICS International for making this
extraordinary conference a possibility.
Brian Sandoval
One Hundred One North
Carson Street
Carson City, Nevada 89701
Office: (775) 684-5670
Fax No.: (775) 684-5683
Expertise Welcome Messages
Greetings from the Nobel Laureate
My Dear Fellows,
We expect that this decade will see great advances in neurosciences. My own work in the area of the
effects of neuro hormones on the brain shows the potential for great strides in this field. Alzheimer’s disease is
the most common cause of age-related dementia in the elderly, characterized by memory loss and cognitive
decline. Alzheimer’s disease degrades the quality of life of patients, puts a major burden on the family and
the caregivers, costs nations around the world billions of dollars annually and has a dismal outcome.
Because the people are living longer the number of individuals afflicted with Alzheimer’s disease is
continuing to climb, creating a major global health problem. We must find new ways to treat this devastating disease.
Conferences like this one may help to speed up the development of effective therapies for neurodegenerative
diseases like Alzheimer’s disease.
Andrew V Schally
Nobel Prize in Physiology/
Medicine for 1977
Greetings from the Mayor
As Mayor of London I am delighted to welcome you to the 5th World Congress on Neurology and
TherapeuticswhichistakingplaceinLondonfrom14-16March2016,organisedbyOMICSInternational
Boris Johnson
Mayor of London
City Hall, London, SE1 2AA
Neurological disorders including dementia will undoubtedly be one of the most significant challenges
in the 21st century and I am pleased that we are hosting such a gathering of eminent experts from London
and across the globe at this important event. London has a long and proud history of scientific and
medical research and the conference will give you an excellent opportunity to network with London’s world class
leaders.

CNS 2016
Central Nervous System Disorders
Central nervous system disorder is a broad category of conditions in which the brain does
not properly function, limiting health and organs functionality. The CNS disorders conditions
include the result of damage from brain cancer, degenerative condition, infection, stroke,
or problems rose from neurological factors. Meningitis is the neuroinfection or inflammation
of the meninges, surrounded by three-layered membranes of the brain, spinal cord and the
fluid and immersed in is called as cerebrospinal fluid. Whereas, Encephalitis which is defined
as inflammation of the layers of tissue or membranes covering the brain. While the complexity
of the central nervous system presents unique challenges for developing novel therapies.
Cognitive Neuroscience
The field of cognitive neuroscience concerns the scientific study of the neural mechanisms
underlying cognition and is a branch of neuroscience. Cognitive neuroscience overlaps
with cognitive psychology, and focuses on the neural substrates of mental processes and
their behavioral manifestations. Methods employed in cognitive neuroscience include
psychophysical experiments, functional neuroimaging, electrophysiological studies of neural
systems and, increasingly, cognitive genomics and behavioral genetics. Clinical studies
in psychopathology in patients with cognitive deficits constitute an important aspect of
cognitive neuroscience.
Neurosurgery
Neurosurgery (or neurological surgery) is the medical specialty concerned with the prevention,
diagnosis, treatment, and rehabilitation of disorders which affect any portion of the nervous
system including the brain, spinal cord, peripheral nerves, and extra-cranial cerebrovascular
system.
Cerebrovascular Disorders
Cerebrovascular disease is a severe, common and expensive disorder. It is third most frequent
cause of death and leading cause of adult disability. Of the 750,000 people suffer stroke
annually 170,000 will die due to stroke. The most common forms of cerebrovascular disease
are cerebral thrombosis (40% of cases) and cerebral embolism (30%), followed by cerebral
haemorrhage.
Brain tumour & Imaging
A brain tumor or intracranial neoplasm occurs when abnormal cells form within the brain. There
are two main types of tumors: malignant or cancerous tumors and benign tumors. Cancerous
tumors can be divided into primary tumors that start within the brain, and secondary tumors
that have spread from somewhere else, known as brain metastasis tumors.
Scientific Highlights

CNS 2016
Spinal Disorders
Spinal disorder may be seen in individuals irrespective of their age -spina bifida in infants to
spinal stenosis in the elderly. There are many types of spinal disorders. The increase in population
with spinal disorders has met with a leap in the advancements in diagnostic techniques. X rays,
MRI, CT, DEA are some of the commonly used tools in diagnosing spinal disorders.
Neurodegenerative Disorders
Neurodegenerative disorder is an umbrella term for a range of conditions which primarily
affect the neurons in the human brain. In some cases, the neurodegenerative diseases are
incurable and debilitating conditions that result in progressive degeneration or death of nerve
cells. These include Alzheimer’s disease (AD) and other dementias, Parkinson’s disease (PD) and
PD-related disorders, Prion disease, Motor neuron diseases (MND), Huntington’s disease (HD),
Spinocerebellar ataxia (SCA), Spinal muscular atrophy and others. Each neurodegenerative
disease is characterized through its unique aggregated protein. ß-amyloid (Aß) represents as
hallmark of Alzheimer’s disease, whereas α-synuclein is the key protein in Parkinson’s disease
and Dementia with Lewy bodies (DLB).
Child Neurology
Paediatric neurology evaluates children with disorders of the central and peripheral nervous
systems. A large proportion in US population suffers from autism, mental retardation, dyslexia,
seizures and other developmental disabilities. Approximately 1,300 U.S children experience
severe or fatal brain trauma from child abuse. Epilepsy is the fourth common neurological
disorder in the US after migraine, stroke, and Alzheimer’s disease. So there is a need to take
into account, the following diseases to dissertate: congenital hydrocephalus, Autism, Neonatal
encephalopathy, Paediatrics tumour, Neurodevelopment disorder, Epilepsy and Child
psychological disorders.
Neuroimmunology
Neuroimmunology is a field of neuroscience, combining immune system and the nervous system.
The immune system administer defence against these organisms, inefficiency of the same results
in Infections. The condition is much worse in developing countries; it has been a significant
health problem in Australia. Some 350,000 to 500,000 patients suffer from multiple sclerosis
(MS) in the United States .The conference on CNS is a platform to put our heads together and
thrash out the cause of Multiple sclerosis and auto immune neuropathies, Neuroimmunological
infectious disease, Neuromicrobial disorders and Neurological Lyme diseases, Neuroinflamation,
Neuroimmuno genetics.
Neuropharmacology
Neuropharmacology means the study of drug effect on the cellular function in the nervous
system. Behavioral neuropharmacology and molecular neuropharmacology are the two

CNS 2016
main branches. Behavioral neuropharmacology focus on the study of drugs effect on human
behavior (neuropsychopharmacology), including the study of drug dependence and addiction
effect on the human brain. Molecular neuropharmacology is the study of neurons and their
neurochemical interactions, with the objective of developing drugs that have beneficial effects
on neurological function.
Neurochemical Transmission
Neurochemistry is the specific study of neurochemicals, including neurotransmitters and
other molecules that include psychopharmaceuticals, neuropeptides, or gastrotransmitters
that influence the function of neurons. It also deals how these neurochemicals influence the
network of neural operation. The studies include micro-macro connection between the analysis
of organic compounds active in the nervous system and neural processes such as cortical
plasticity, neurogenesis and neural differentiation, synapses, autism and intellectual disability,
interneuronal coordination, interaction of drugs and its effect on summation and cotransmission
process and advances in astrocyte-neuron interactions in health.
Novel drug development & its effects
Drug development is the process of bringing a new pharmaceutical drug to the market once
a lead compound has been identified through the process of drug discovery. It includes pre-
clinical research on microorganisms and animals, clinical trials on humans, and may include the
step of obtaining regulatory approval to market the drug.
Computational Neurosciences
Computational Neuroscience (CN) is strictly defined as the quantitative understanding of the
function of the brain at the level of neuronal dynamics and neural networks. Natural outputs
of CN studies are dynamic network models of brain regions or processes that, via computer
simulation, provide a theoretical foundation and technology that enhances our understanding
of their function.
Case Study on CNS
Neurology is a special branch of medical Sciences that deals primarily with the disorders in the
central nervous system. Neurophysiology is a union of both neurology and physiology and it
studies the functioning of the nervous system.
Clinical Trials on CNS
With an ever increasing average life expectancy, neurodegenerative diseases are becoming
more prevalent in society. The economic and social costs of neurodegenerative disorders to
society are huge. Many big pharmaceutical companies have moved away from CNS research.
With this comes the need for new and improved therapies for treating neurodegenerative
conditions. From Alzheimer’s to Parkinson’s disease, the target and mechanism by which a
disease manifests itself presents unique challenges in how to approach such treatments not to
mention ethical and legal issues behind treatment and trial design.

CNS 2016
CNS Biomarkers
A biomarker can be defined as a biological variable that has a statistically significant relationship
with parameters of disease states or the activity of a drug or drug candidate. Biomarkers are
fast becoming an essential part of clinical development, largely because they: (i) offer the
prospect of more homogenous patient populations in clinical trials through patient selection
and stratification; (ii) permit assessment of target engagement; (iii) allow the consequences of
target engagement to be measured; and (iv) provide markers of disease modification.
Neurological Nursing
Neurological Nursing is a very challenging nursing specialty dealing with assessment, nursing
diagnosis, and management of many neurological disorders for which nurses provide patient
care. This includes trauma, brain injuries, stroke, seizures, tumors, headaches, infections, and
aneurysms, as well as a host of other neurological complexities.

CNS 2016

CNS 2016
Central Nervous System-2012 Report
The International Conference & Exhibition on Central Nervous System - Drug Effects & Novel
Drug Development, hosted by the OMICS Group was held on September 05-07, 2012 at Double
Tree by Hilton Philadelphia Center City, USA. Generous response and active participation
was received from the Editorial Board Members of OMICS Group Journals as well as from
neurologists, researchers and leaders from pharma, government organizations who made
this conference as one of most successful and productive events in 2012 from OMICS Group.
The conference was carried out through various sessions, in which the discussions were held
on the following scientific tracks
• Alzheimer’s Disease
• Disorders related to CNS
• Behavioral Neurology
• Clinical Neurophysiology
• Oncology of Central Nervous System
• Neurodegenerative Diseases
• Remedies for CNS & Neurological Disorders
• CNS Biomarkers
• Clinical Trials on CNS
• Drug Metabolism in Drug Design and Drug Interactions
• Neural Stem Cells and Gene or Cell Therapy
• Neuroimmunology
• Neuromics & Human Brain proteome
• Perspectives in Neurology Research
• Neurorehabilitation
• Epilepsy
• Cerebral CSF Flow Studies
• Diagnosis for cerebral infections
The conference was initiated with a prominent keynote speaker, Dr. Giulio Maria Pasinetti
from Mount Sinai School of Medicine, USA, The above mentioned keynote speaker gave his
energetic and fruitful contributions at Central Nervous System-2012.
All accepted abstracts have been indexed in OMICS Group Journal of Neurology &
Neurophysiology as a special issue.
We are also obliged to various outside experts, company representatives and other eminent
personalities who supported the conference by facilitating the discussion forums. Our sincere
thanks to Organizing Committee Members for their gracious presence, support and assistance
towards Central Nervous System -2012, and with their unique feedback, OMICS Group would
like to announce the “2nd
International Conference on Central Nervous System disorders and
Therapeutics” to be held at Dubai, UAE on December 05-07, 2016.
Past Conference Report

CNS 2016
• Central nervous system tumors are the most common cancers among children ages 0-19.
• The majority of primary tumors (34%) are located within the meninges, followed by those
located within the frontal, temporal, parietal and occipital lobes of the brain (22%).
• In 2006-2010, the average annual age-adjusted incidence rate of all primary malignant
brain and CNS tumors was 7.27 & the average annual age-adjusted incidence rate of
non-malignant brain and CNS tumors was 13.77.
• Glioblastomas represent 17% of all primary brain tumors, and 54% of all gliomas.
• CNS and brain tumours were the ninth most common cancer in the UK (2012), accounting
for 3% of all new cases. They are the 11th most common cancers in males (3% of the male
total) and the eighth most common in females (3%).
• In 2012, 9,678 new brain, other CNS and intracranial tumour cases were registered in the UK
4,760 (49%) in men and 4,918 (51%) in women, giving a male:female ratio of around 10:10.
The crude incidence rate shows that there are 15 new brain, other CNS and intracranial
tumour cases for every 100,000 males in the UK and 15 for every 100,000 females.
• Advanced radiation therapy techniques that target tumor tissue more precisely and
reduce radiation damage to surrounding normal tissue (such as 3-dimensional conformal
therapy, stereotactic radiation therapy, and intensity-modulated radiation therapy) are
being refined.
• A new scale developed by NIH, which is based on tumor size, tumor location, and a
patient’s ability to perform everyday tasks, can help surgeons identify which patients with
glioblastoma will benefit from additional surgery when their tumor recurs.
• In 2008, The Cancer Genome Atlas (TCGA) project reported the first results of its large-scale,
comprehensive study of gene changes in glioblastoma (a type of glioma). These results
identified three previously unrecognized mutations that occur frequently in glioblastoma
and three cell-signaling pathways that may help drive tumor growth. The results also shed
newlightonmolecularmechanismsthatmaymaketumorsresistanttosomechemotherapy
drugs. In 2010, additional results from TCGA showed that glioblastoma comprises four
different molecular subtypes that have different responses to chemotherapy and radiation
therapy.
• Despite tremendous advances in our understanding of brain cancer biology, substantial
progress in brain tumor diagnosis and treatment, and marked improvements in the quality
of life of brain tumor patients, the mortality rate for brain and other CNS cancers has
remained largely unchanged over the past 30 to 40 years.
CNS Market Statistics

CNS 2016
Dubai is the most populated city in the UAE with residents of 2.2 million. Dubai is global business city and
cultural hub of the Middle East and the Persian Gulf region. It is one of the countries of MENA which has
international network of research with higher-education Institutions, transport, business, communication, events
and conference hub bridging healthcare professionals from the seven continents annually to collaborate and
exchange knowledge and research.
Dubai’s attraction lies in the contrast between the ultra-modern and the enchantingly traditional, which
gives the city a personality like no other and visitors a variety of experiences to choose from. From desert oases
and unspoiled beaches, camel races and old wind towers, to top-class shopping opportunities, avant-garde
architecture and the finest international cuisine, Dubai has more than enough depth to satisfy even the most
seasoned of travellers.
Why Dubai??
• Dubai is the most populated city in the UAE with residents of 2.2 million. Dubai is global business city and
cultural hub of the Middle East and the Persian Gulf region.
• Dubai is place of eventsand conference hub bridging healthcare professionals from the seven continents
annually to collaborate and exchange knowledge and research.
• Dubai is an upcoming global leader in medical innovation and research.
• The medical tourism is expected to attract more than 500,000 patients per year and boost its economy by up
to $2.6 billion by 2020.
• It is one of the countries of MENA which has international network of research with higher-education Institutions,
transport, business and communication.
• Air flights take 14 hours from US, 5hours from Europe and 3hours from most parts of the Middle East and Asia.
• Dubai won the bid to host EXPO 2020, a Universal scale Registered Exposition approved by the Bureau of
International Expositions (BIE), Paris
About Dubai, UAE
Important Dates
Abstract submission opens: December 10, 2015
Registration opens: December 10, 2015
Early bird registration: February 10, 2016
On spot registration: December 05, 2016

CNS 2016
Venue
Dubai, UAE
Register online: http://cns.conferenceseries.com/registration.php
Registration Benefits
• Contribute to and learn about the most recent advances in Neurology field
• Accepted abstract will be published in respective OMICS journals
• Each abstract will receive a Digital Object Identifier (DOI) provided by crossref
• Conference will contribute to increment in overall research profile
• Golden chance to meet other researchers in neurology field and potential contacts for future positions
• International platform for presentation skills and expertise to discuss the research in clear and meaningful way
Important Links

CNS 2016
Special Issues
All accepted abstracts will be published in respective OMICS International Journals
Each abstract will be provided with digital Object Identifier by
About Us
OMICS International Journals
• 700+ Open Access Journals
• Scholarly Journals Index- PubMed, ISI, Scopus,
Chemical Abstracts Service, ProQuest, Gale EBSCO
• 21 Days rapid review process
• 70000 Editorial Team
• Publication immediately after acceptance
• Quality and quick editorial, review processing
Key features
• User friendly/feasible website translation of your
paper to 50 world’s leading languages
• Enhanced feature: Audio version of published paper
• Digital articles to share and explore
• Sharing option: Social networking enabled
• Authors, reviewers and editors are provided with
scientific credits
OMICS International Conferences
• 3000+ Global Events with over 600+ Conferences,
1200+ Symposiums and 1200+ Workshops
• 15 Million unique visitors/year (36 million page
views/year)
• Well organized scientific program
• Renowned speakers and scientists across the
globe
• Poster presentations and world class exhibits
• Panel discussions and interactive sessions
• B2B meetings
• Perfect platform for Global Networking
Key features
• Presentation by renowned speakers from all over
the world
• Poster presentations and world class exhibits
• Interactive Sessions
• Live Streaming Conferences and Meetings
• Platform for global networking
• Connecting scientific community

CNS 2016
CNS 2016 aims to fasten the advancement of scientific knowledge that may ultimately result in a
better prognosis for patients. International conference is the best platform to develop new partnership &
collaborations .It provides an important base for the exchange of knowledge and experience amongst the
clinicians. The internationally renowned speakers at this conference will explore the various aspects of
Central Nervous System disorders and Therapeutics.
CNS 2016
• Opportunity to attend the presentations delivered by eminent scientists from all over the world
• Selected contributions will be published in following OMICS International Journals
• Current Neurobiology
• Journal of Neurological Disorders
• Journal of Neurology and Neuroscience
• Journal of Neurology & Neurophysiology
• Participation in sessions on specific topics on which the conference is expected to achieve
progress
• Global networking: In transferring and exchanging Ideas
• Conference brings together Scientific Researchers, Safety Professionals, Regulatory Authorities,
Principal Investigators, Business Entrepreneurs, and Industry Developers.

CNS 2016_Brochure

Recommended

Recommended

More Related Content

Viewers also liked

Viewers also liked (8)

Similar to CNS 2016_Brochure

Similar to CNS 2016_Brochure (20)

CNS 2016_Brochure